- Total Revenue, Products & Services Revenue, Instrument and Consumable Sales All Increased Y/Y;
BaroFold IP Acquisition, Collaborations, Expanded Sales Team Expected to Fuel Growth.
- Company Announces Conversion of $6.39M of Convertible Debentures into Equity
- Investor Conference Call Scheduled for Tuesday, May 15, 2018 at 4:30 PM EDT
SOUTH EASTON, MA / ACCESSWIRE / May 15, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the
"Company"), a leader in the development and sale of broadly enabling, pressure-based instruments and consumables to the worldwide
life sciences industry, today announced financial results for the first quarter ended March 31, 2018, provided a business update,
and offered limited guidance for FY2018.
Financial Results: Q1 2018 vs. Q1 2017
Products and services revenue was $585,244 for the first quarter of 2018 compared to $525,998 for the same quarter of 2017, a
11% increase. Sales of instruments increased to $420,089 in Q1 2018 compared to $396,095 in Q1 2017, an increase of 8%. Sales of
consumables were $74,698 for the first quarter of 2018 compared to $63,264 for the same period in 2017, an 18% increase. Grant
revenue in Q1 2018 was $25,530 compared to $25,359 in Q1 2017.
Total revenue for the first quarter ended March 31, 2018 was $610,774 compared to $551,357 for the same period in 2017, an 11%
increase. This increase was primarily due to our double-digit growth in products and services.
Operating loss for Q1 2018 was $1,108,064 compared to $999,103 for the same period in 2017. This increase was due primarily to
headcount increases in sales and marketing and to research collaboration costs.
Loss per common share - basic and diluted - was $(1.64) for Q1 2018 compared to loss per common share of $(2.16) for the same
period in 2017.
Recent Operational & Technical Highlights
- We approved the conversion of $6.39M of Debentures held by 22 (of 36) debt holders into Series AA Preferred Stock (equity),
which represents 92% of the amount of all 2015/2016 Debentures outstanding.
- We announced receipt of the first contract utilizing PBI’s recently acquired high pressure technology from BaroFold, Inc. to
evaluate the ability of our patented PreEMT platform to improve the manufacturing process for robust production and maintenance
of the quality and efficacy of protein therapeutic drug candidates.
- We announced a two-year, worldwide co-marketing and distribution agreement with ISS, Inc., a global supplier of high pressure
optical cell systems used in many types of laboratory analytical processes. The companies plan to replace the current manual
pressure generator used for the ISS optical cell with PBI's computer-controlled, automated instruments.
- We reported Q4 and FY2017 financial results and offered a business update. Instruments, consumables, products & services and
total revenue continued to show double-digit growth. Quarterly revenue increased for eight quarters in a row, on a Y/Y basis.
Total annual revenue increased for the third year in a row, on a Y/Y basis.
Mr. Joseph L. Damasio, VP of Finance and CFO of PBI, commented: "We reported a number of significant financial accomplishments
for the first quarter of 2018. Key among these was the continued growth in our products and services area, especially in the sale
of instruments (a new quarterly record) and consumables (up 18%). Q1 2018 was the ninth consecutive quarter in which we reported an
increase in products and services revenue on a Y/Y basis. For the second time in the past year, total quarterly revenue exceeded
$600,000."
Mr. Richard T. Schumacher, President and CEO of PBI, commented: "In addition to these Q1 2018 financial accomplishments, we
reported several noteworthy operational successes as well. First, we negotiated and signed the first biological services contract
requiring the use of our patented PreEMT technology platform recently acquired from BaroFold, Inc. Second, we announced a
collaboration with ISS, Inc – a major U.S. spectrometry manufacturer whose customers will consequently be able to benefit from the
use of our automated pressure generating equipment. Finally, Q1 2018 was the first time that all three of our recently-hired and
trained sales directors were in their territories during an entire quarter."
Mr. Schumacher continued: "Perhaps most exciting was the news released just today – that a majority of our 2015/2016 Convertible
Debenture Holders have agreed to convert approximately $6.39M of Debentures into Series AA Preferred Stock. This represents about
92% of all 2015/2016 Debenture debt on our balance sheet as of March 31, 2018. Furthermore, we believe that most if not all of the
remaining Debenture holders will follow suit and request conversion of their Debenture debt into the Series AA Preferred Stock in
the very near future."
Mr. Schumacher concluded: "We are in discussions with other Note holders about the possible conversion of debt into equity in
the near future. Combined with today's conversion of the majority of the 2015/2016 Debentures, if some of these additional loans
are also converted into equity, the projected balance sheet on June 30, 2018 will be materially stronger than the balance sheet as
of March 31, 2018. We believe that such a change would have a significant, positive effect on the growth of PBI going forward, and
would materially enhance our stated objective of up-listing to a national exchange (NASDAQ, NYSE/Amex) later in 2018."
Earnings Call
The Company will hold an Earnings Conference Call at 4:30 PM EDT on Tuesday, May 15, 2018. To attend this teleconference via
telephone, Dial-in: (877) 407-8033 (North America), (201) 689-8033 (International). Verbal Passcode: PBIO First Quarter 2018
Financial Results Call. Replay Number (877) 481-4010; (919) 882-2331 (International). Replay ID Number: 33422. Teleconference
Replay Available for 30 days.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based
solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static)
and alternating (i.e., pressure cycling technology, or "PCT") hydrostatic pressure. PCT is a patented enabling technology platform
that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control
bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based
products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control,
soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in
the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from
BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of our recently-patented,
scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nanoemulsions of otherwise
immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature
stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual
results, levels of activity, performance or achievements to be materially different from any future results, levels of activity,
performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based on our current expectations and projections about future
events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider
various factors. Actual events or results may differ materially. The Company's financial results for the first three months ended
March 31, 2018 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ
materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the
risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended
December 31, 2017, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to
update any of the information included in this release, except as otherwise required by law.
For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.
Investor Contacts:
Richard T. Schumacher, President and CEO
(508) 230-1828 (T)
Joseph L. Damasio, VP of Finance and CFO
(508) 230-1829 (F)
PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
Unaudited
For the Three Months
Ended
March,
|
|
|
|
2018
|
|
|
2017
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
Products, services, other
|
|
$
|
585,244
|
|
|
$
|
525,998
|
|
|
Grant revenue
|
|
|
25,530
|
|
|
|
25,359
|
|
|
Total revenue
|
|
|
610,774
|
|
|
|
551,357
|
|
|
|
|
|
|
|
|
|
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
|
Cost of products and services
|
|
|
324,789
|
|
|
|
235,997
|
|
|
Research and development
|
|
|
324,976
|
|
|
|
263,456
|
|
|
Selling and marketing
|
|
|
274,468
|
|
|
|
213,009
|
|
|
General and administrative
|
|
|
794,605
|
|
|
|
837,998
|
|
|
Total operating costs and expenses
|
|
|
1,718,838
|
|
|
|
1,550,460
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(1,108,064)
|
|
|
|
(999,103)
|
|
|
|
|
|
|
|
|
|
|
|
Other (expense) income:
|
|
|
|
|
|
|
|
|
|
Interest expense, net
|
|
|
(1,123,145)
|
|
|
|
(1,240,373)
|
|
|
Other expense
|
|
|
-
|
|
|
|
(959)
|
|
|
Impairment loss on investment
|
|
|
(4,730)
|
|
|
|
(6,069)
|
|
|
Gain on extinguishment of debt
|
|
|
4,285
|
|
|
|
-
|
|
|
Total other expense
|
|
|
(1,123,590)
|
|
|
|
(1,247,401)
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
(2,231,654)
|
|
|
|
(2,246,504)
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share - basic and diluted
|
|
$
|
(1.64)
|
|
|
$
|
(2.16)
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation
|
|
|
1,363,326
|
|
|
|
1,040,769
|
|
PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
|
|
Unaudited
March 31,
2018
|
|
|
December 31,
2017
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
CURRENT ASSETS
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
81,162
|
|
|
$
|
81,033
|
|
|
Accounts receivable
|
|
|
322,584
|
|
|
|
206,848
|
|
|
Inventories, net of $159,650 reserve at March 31, 2018 and $179,600 at December 31, 2017
|
|
|
892,407
|
|
|
|
857,662
|
|
|
Prepaid expenses and other current assets
|
|
|
199,272
|
|
|
|
222,158
|
|
|
Total current assets
|
|
|
1,495,425
|
|
|
|
1,367,701
|
|
|
Intangible assets, net of amortization of $21,635 and $0, respectively
|
|
|
728,365
|
|
|
|
750,000
|
|
|
Investment in available-for-sale equity securities
|
|
|
15,095
|
|
|
|
19,825
|
|
|
Property and equipment, net
|
|
|
20,798
|
|
|
|
22,662
|
|
|
TOTAL ASSETS
|
|
$
|
2,259,683
|
|
|
$
|
2,160,188
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' DEFICIT
|
|
|
|
|
|
|
|
|
|
CURRENT LIABILITIES
|
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
641,086
|
|
|
$
|
589,263
|
|
|
Accrued employee compensation
|
|
|
353,032
|
|
|
|
368,700
|
|
|
Accrued professional fees and other
|
|
|
796,487
|
|
|
|
800,620
|
|
|
Other current liabilities
|
|
|
2,003,603
|
|
|
|
1,536,507
|
|
|
Deferred revenue
|
|
|
235,311
|
|
|
|
263,106
|
|
|
Revolving note payable
|
|
|
4,000,000
|
|
|
|
3,500,000
|
|
|
Related party debt, net of debt discount of $7,151 and $0, respectively
|
|
|
42,849
|
|
|
|
-
|
|
|
Related party convertible debt, net of debt discount of $34,973 and $31,372, respectively
|
|
|
256,161
|
|
|
|
259,762
|
|
|
Convertible debt, net of unamortized debt discounts of $327,170 and $401,856, respectively
|
|
|
8,914,450
|
|
|
|
8,028,014
|
|
|
Other debt, net of unamortized discounts of $30,175 and $48,194, respectively
|
|
|
1,448,673
|
|
|
|
1,379,863
|
|
|
Total current liabilities
|
|
|
18,691,652
|
|
|
|
16,725,835
|
|
|
LONG TERM LIABILITIES
|
|
|
|
|
|
|
|
|
|
Deferred revenue
|
|
|
49,537
|
|
|
|
57,149
|
|
|
TOTAL LIABILITIES
|
|
|
18,741,189
|
|
|
|
16,782,984
|
|
|
COMMITMENTS AND CONTINGENCIES
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS' DEFICIT
|
|
|
|
|
|
|
|
|
|
Series D Convertible Preferred Stock, $.01 par value; 850 shares authorized; 300 shares issued and outstanding on March
31, 2018 and December 31, 2017, respectively (Liquidation value of $300,000)
|
|
|
3
|
|
|
|
3
|
|
|
Series G Convertible Preferred Stock, $.01 par value; 240,000 shares authorized; 80,570 shares issued and outstanding on
March 31, 2018 and December 31, 2017, respectively
|
|
|
806
|
|
|
|
806
|
|
|
Series H Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; 10,000 shares issued and outstanding on
March 31, 2018 and December 31, 2017, respectively
|
|
|
100
|
|
|
|
100
|
|
|
Series H2 Convertible Preferred Stock, $.01 par value; 21 shares authorized; 21 shares issued and outstanding on March
31, 2018 and December 31, 2017, respectively
|
|
|
-
|
|
|
|
-
|
|
|
Series J Convertible Preferred Stock, $.01 par value; 6,250 shares authorized; 3,458 shares issued and outstanding on
March 31, 2018 and December 31, 2017, respectively
|
|
|
35
|
|
|
|
35
|
|
|
Series K Convertible Preferred Stock, $.01 par value; 15,000 shares authorized; 6,880 shares issued and outstanding on
March 31, 2018 and December 31, 2017, respectively
|
|
|
68
|
|
|
|
68
|
|
|
Series AA Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; 0 shares issued and outstanding on March
31, 2018 and December 31, 2017, respectively
|
|
|
-
|
|
|
|
-
|
|
|
Common stock, $.01 par value; 100,000,000 shares authorized; 1,388,214 and 1,342,858 shares issued and outstanding on
March 31, 2018 and December 31, 2017, respectively
|
|
|
13,882
|
|
|
|
13,429
|
|
|
Warrants to acquire common stock
|
|
|
9,996,929
|
|
|
|
9,878,513
|
|
|
Additional paid-in capital
|
|
|
31,087,624
|
|
|
|
30,833,549
|
|
|
Accumulated deficit
|
|
|
(57,580,953)
|
|
|
|
(55,349,299)
|
|
|
Total stockholders' deficit
|
|
|
(16,481,506)
|
|
|
|
(14,622,796)
|
|
|
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT
|
|
$
|
2,259,683
|
|
|
$
|
2,160,188
|
|
SOURCE: Pressure BioSciences, Inc.
